This follows the Government's announcement that the
Shareholders will be notified of the time and place of the adjourned meeting within the next 10 days.
AFT appreciates the support and understanding of shareholders with regard to this adjournment and apologises for any inconvenience. We believe this is the prudent response in the circumstances to protect the health and safety of all involved and to comply with the guidelines announced by the Government.
Contact:
Dr
Tel: +64 9 488 0232
About
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of
(C) 2020 Electronic News Publishing, source